Detection of CD30 expression in lymphomas: status and challenges

Xiaoqiu LI

doi:10.19401/j.cnki.1007-3639.2022.06.005

您当前的位置：

首页 >

文章列表页 >

Detection of CD30 expression in lymphomas: status and challenges

Specialists' Commentary | 更新时间：2025-12-31

- Detection of CD30 expression in lymphomas: status and challenges
- China Oncology Vol. 32, Issue 6, Pages: 512-518(2022)
- 作者机构：
  
  复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032
- 作者简介：
  
  LI Xiaoqiu E-mail: leexiaoqiu@hotmail.com
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.06.005
  CLC： R733.4
- Received：07 March 2022，
  
  Revised：2022-05-30，
  
  Published：30 June 2022
- 稿件说明：
移动端阅览
Xiaoqiu LI. Detection of CD30 expression in lymphomas: status and challenges[J]. China Oncology, 2022, 32(6): 512-518.
DOI：

Xiaoqiu LI. Detection of CD30 expression in lymphomas: status and challenges[J]. China Oncology, 2022, 32(6): 512-518. DOI： 10.19401/j.cnki.1007-3639.2022.06.005.

摘要

CD30是肿瘤坏死因子受体超家族成员

在经典型霍奇金淋巴瘤（classical Hodgkin lymphoma

CHL）、间变性大细胞淋巴瘤（anaplastic large cell lymphoma

ALCL）等多种淋巴瘤中均有不同程度的表达。除了作为诊断和评价预后的标志物

CD30还是抗体药物偶联物的有效靶点。随着以CD30为治疗靶点的多项临床试验相继开展

淋巴瘤CD30表达水平的规范化检测日益重要。本文综述了CD30在不同类型淋巴瘤中的表达特征以及CD30在检测和判读方面所面临的挑战及可能的解决方案。

Abstract

CD30

a member of tumor necrosis factor receptor family

is expressed in a variety of lymphoma subtypes

such as classic Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL). In addition to its diagnostic and prognostic values

CD30 has now been recognized as an effective target for antibody drug conjugate (ADC). With the progress of multiple clinical trials involving the anti-CD30-targeted therapy

a standardized detection and assessment of CD30 expression in lymphoma cases appear necessary. We thus reviewed in this article the CD30 expression patterns and the challenges on the CD30 detection and assessment in different lymphomas.

关键词

Keywords

references

HORIE R , AIZAWA S , NAGAI M , et al . A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation [J ] . Int Immunol , 1998 , 10 ( 2 ): 203 - 210 . DOI: 10.1093/intimm/10.2.203 http://doi.org/10.1093/intimm/10.2.203 https://academic.oup.com/intimm/article-lookup/doi/10.1093/intimm/10.2.203 https://academic.oup.com/intimm/article-lookup/doi/10.1093/intimm/10.2.203

VAN DER WEYDEN C A , PILERI S A , FELDMAN A L , et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions [J ] . Blood Cancer J , 2017 , 7 ( 9 ): e603 . DOI: 10.1038/bcj.2017.85 http://doi.org/10.1038/bcj.2017.85 http://www.nature.com/articles/bcj201785 http://www.nature.com/articles/bcj201785

ROMAGNANI P , ANNUNZIATO F , MANETTI R , et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus [J ] . Blood , 1998 , 91 ( 9 ): 3323 - 3332 . DOI: 10.1182/blood.V91.9.3323 http://doi.org/10.1182/blood.V91.9.3323 https://ashpublications.org/blood/article/91/9/3323/244093/High-CD30-Ligand-Expression-by-Epithelial-Cells https://ashpublications.org/blood/article/91/9/3323/244093/High-CD30-Ligand-Expression-by-Epithelial-Cells

BOWEN M A , LEE R K , MIRAGLIOTTA G , et al . Structure and expression of murine CD30 and its role in cytokine production [J ] . J Immunol , 1996 , 156 ( 2 ): 442 - 449 .

PIERCE J M , MEHTA A . Diagnostic, prognostic and therapeutic role of CD30 in lymphoma [J ] . Expert Rev Hematol , 2017 , 10 ( 1 ): 29 - 37 . DOI: 10.1080/17474086.2017.1270202 http://doi.org/10.1080/17474086.2017.1270202 https://www.tandfonline.com/doi/full/10.1080/17474086.2017.1270202 https://www.tandfonline.com/doi/full/10.1080/17474086.2017.1270202

FEDERICO M , BELLEI M , LUMINARI S , et al . CD30 + expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-Cell Project [J ] . J Clin Oncol , 2015 , 33 ( 15_suppl ): 8552 . DOI: 10.1200/jco.2015.33.15_suppl.8552 http://doi.org/10.1200/jco.2015.33.15_suppl.8552 https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.8552 https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.8552

PONGPRUTTIPAN T , KUMMALUE T , BEDAVANIJA A , et al . Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand [J ] . Diagn Pathol , 2011 , 6 : 79 . DOI: 10.1186/1746-1596-6-79 http://doi.org/10.1186/1746-1596-6-79 https://doi.org/10.1186/1746-1596-6-79 https://doi.org/10.1186/1746-1596-6-79

FERRERI A J M , GOVI S , PILERI S A , et al . Anaplastic large cell lymphoma, ALK-positive [J ] . Crit Rev Oncol , 2012 , 83 ( 2 ): 293 - 302 . DOI: 10.1016/j.critrevonc.2012.02.005 http://doi.org/10.1016/j.critrevonc.2012.02.005 https://linkinghub.elsevier.com/retrieve/pii/S1040842812000443 https://linkinghub.elsevier.com/retrieve/pii/S1040842812000443

DELSOL G , FALINI B , MULLERHERMELINK HK , et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO classification of tumours of haematopoietic & lymphoid tissues, 2008 [EB/OL ] .[2008-01-01 ] .https://www.researchgate.net/scientific-contributions/HK-Muller-Hermelink-2127932347 https://www.researchgate.net/scientific-contributions/HK-Muller-Hermelink-2127932347 https://www.researchgate.net/scientific-contributions/HK-Muller-Hermelink-2127932347 .

SABATTINI E , PIZZI M , TABANELLI V , et al. CD30 expression in peripheral T-cell lymphomas [J ] . Haematologica , 2013 , 98 ( 8 ): e81-e82 .

EDINGER J T , CLARK B Z , PUCEVICH B E , et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides [J ] . Am J Surg Pathol , 2009 , 33 ( 12 ): 1860 - 1868 . DOI: 10.1097/PAS.0b013e3181bf677d http://doi.org/10.1097/PAS.0b013e3181bf677d https://journals.lww.com/00000478-200912000-00016 https://journals.lww.com/00000478-200912000-00016

CERRONI L , RIEGER E , HÖDL S , et al . Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma [J ] . Am J Surg Pathol , 1992 , 16 ( 6 ): 543 - 552 . DOI: 10.1097/00000478-199206000-00002 http://doi.org/10.1097/00000478-199206000-00002 http://journals.lww.com/00000478-199206000-00002 http://journals.lww.com/00000478-199206000-00002

EL SHABRAWI-CAELEN L , KERL H , CERRONI L . Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C [J ] . Arch Dermatol , 2004 , 140 ( 4 ): 441 - 447 .

SLACK G W , STEIDL C , SEHN L H , et al. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia [J ] . Br J Haematol , 2014 , 167 ( 5 ): 608 - 617 . DOI: 10.1111/bjh.13085 http://doi.org/10.1111/bjh.13085 https://onlinelibrary.wiley.com/doi/10.1111/bjh.13085 https://onlinelibrary.wiley.com/doi/10.1111/bjh.13085

CAMPUZANO-ZULUAGA G , CIOFFI-LAVINA M , LOSSOS I S , et al . Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases [J ] . Leuk Lymphoma , 2013 , 54 ( 11 ): 2405 - 2411 . DOI: 10.3109/10428194.2013.778407 http://doi.org/10.3109/10428194.2013.778407 https://www.tandfonline.com/doi/full/10.3109/10428194.2013.778407 https://www.tandfonline.com/doi/full/10.3109/10428194.2013.778407

HU S M , XU-MONETTE Z Y , BALASUBRAMANYAM A , et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL rituximab-CHOP consortium program study [J ] . Blood , 2013 , 121 ( 14 ): 2715 - 2724 . DOI: 10.1182/blood-2012-10-461848 http://doi.org/10.1182/blood-2012-10-461848 https://ashpublications.org/blood/article/121/14/2715/31153/CD30-expression-defines-a-novel-subgroup-of https://ashpublications.org/blood/article/121/14/2715/31153/CD30-expression-defines-a-novel-subgroup-of

HIGGINS J P , WARNKE R A . CD30 expression is common in mediastinal large B-cell lymphoma [J ] . American J Clin Pathol , 1999 , 112 ( 2 ): 241 - 247 . DOI: 10.1093/ajcp/112.2.241 http://doi.org/10.1093/ajcp/112.2.241 https://academic.oup.com/ajcp/article-lookup/doi/10.1093/ajcp/112.2.241 https://academic.oup.com/ajcp/article-lookup/doi/10.1093/ajcp/112.2.241

GARDNER L J , POLSKI J M , EVANS H L , et al. CD30 expression in follicular lymphoma [J ] . Archiv Pathol Laboratory Med , 2001 , 125 ( 8 ): 1036 - 1041 . DOI: 10.5858/2001-125-1036-CEIFL http://doi.org/10.5858/2001-125-1036-CEIFL https://meridian.allenpress.com/aplm/article/125/8/1036/453144/CD30-Expression-in-Follicular-Lymphoma https://meridian.allenpress.com/aplm/article/125/8/1036/453144/CD30-Expression-in-Follicular-Lymphoma

ANSELL S M . Hodgkin lymphoma: diagnosis and treatment [J ] . Mayo Clin Proc , 2015 , 90 ( 11 ): 1574 - 1583 . DOI: 10.1016/j.mayocp.2015.07.005 http://doi.org/10.1016/j.mayocp.2015.07.005 https://linkinghub.elsevier.com/retrieve/pii/S0025619615005509 https://linkinghub.elsevier.com/retrieve/pii/S0025619615005509

MORA J , FILIPPA D A , THALER H T , et al . Large cell non-Hodgkin lymphoma of childhood [J ] . Cancer , 2000 , 88 ( 1 ): 186 - 197 . DOI: 10.1002/(SICI)1097-0142(20000101)88:1&lt;186::AID-CNCR26&gt;3.0.CO;2-5 http://doi.org/10.1002/(SICI)1097-0142(20000101)88:1&lt;186::AID-CNCR26&gt;3.0.CO;2-5 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000101)88:1&lt;186::AID-CNCR26&gt;3.0.CO;2-5 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000101)88:1&lt;186::AID-CNCR26&gt;3.0.CO;2-5

KRAUSE J R . WHO classification of tumours of haematopoietic and lymphoid tissues: an overview [J ] . Crit Values , 2015 , 2 ( 2 ): 30 - 32 .

WEISENBURGER D D , SAVAGE K J , HARRIS N L , et al . Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project [J ] . Blood , 2011 , 117 ( 12 ): 3402 - 3408 . DOI: 10.1182/blood-2010-09-310342 http://doi.org/10.1182/blood-2010-09-310342 https://ashpublications.org/blood/article/117/12/3402/20442/Peripheral-Tcell-lymphoma-not-otherwise-specified https://ashpublications.org/blood/article/117/12/3402/20442/Peripheral-Tcell-lymphoma-not-otherwise-specified

HOFFBRAND A , CATOVSKY D , TUDDENHAM E , et al . Appendix Ⅱ: World Health Organization classification of tumours of the haematopoietic and lymphoid tissues [EB/OL ] . https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b , 2010.

FALINI B , PILERI S , PIZZOLO G , et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy [J ] . Blood , 1995 , 85 ( 1 ): 1 - 14 . DOI: 10.1182/blood.V85.1.1.bloodjournal8511 http://doi.org/10.1182/blood.V85.1.1.bloodjournal8511 https://ashpublications.org/blood/article/85/1/1/122542/CD30-Ki1-molecule-a-new-cytokine-receptor-of-the https://ashpublications.org/blood/article/85/1/1/122542/CD30-Ki1-molecule-a-new-cytokine-receptor-of-the

EL-SAYED A M , EL-BORAI M H , BAHNASSY A A , et al . Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry [J ] . Diagn Pathol , 2008 , 3 : 43 . DOI: 10.1186/1746-1596-3-43 http://doi.org/10.1186/1746-1596-3-43

Nordic Immunohistochemical Quality Control, CD30 run 51 2017 .[EB/OL ] .[20 17-11-27 ] . https://www.nordiqc.org/downloads/assessments/90_5.pdf https://www.nordiqc.org/downloads/assessments/90_5.pdf. https://www.nordiqc.org/downloads/assessments/90_5.pdf.

LI B , ESCHRICH S A , BERGLUND A , et al . Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility [J ] . JMIR Res Protoc , 2017 , 6 ( 3 ): e45.

XU M L , GABALI A , HSI E D , et al . Practical approaches on CD30 detection and reporting in lymphoma diagnosis [J ] . Am J Surg Pathol , 2020 , 44 ( 2 ): e1-e14.

HORWITZ S , O'CONNOR O A , PRO B , et al . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [J ] . Lancet , 2019 , 393 ( 10168 ): 229 - 240 . DOI: 10.1016/S0140-6736(18)32984-2 http://doi.org/10.1016/S0140-6736(18)32984-2 https://linkinghub.elsevier.com/retrieve/pii/S0140673618329842 https://linkinghub.elsevier.com/retrieve/pii/S0140673618329842

FANALE M A , HORWITZ S M , FORERO-TORRES A , et al . Brentuximab vedotin in the front-line treatment of patients with CD30 + peripheral T-cell lymphomas: results of a phase I study [J ] . J Clin Oncol , 2014 , 32 ( 28 ): 3137 - 3143 . DOI: 10.1200/JCO.2013.54.2456 http://doi.org/10.1200/JCO.2013.54.2456 https://ascopubs.org/doi/10.1200/JCO.2013.54.2456 https://ascopubs.org/doi/10.1200/JCO.2013.54.2456

DUVIC M , TETZLAFF M T , GANGAR P , et al . Results of a phase & #x02161; trial of brentuximab vedotin for CD30 + cutaneous T-cell lymphoma and lymphomatoid papulosis [J ] . J Clin Oncol , 2015 , 33 ( 32 ): 3759 - 3765 . DOI: 10.1200/JCO.2014.60.3787 http://doi.org/10.1200/JCO.2014.60.3787 https://ascopubs.org/doi/10.1200/JCO.2014.60.3787 https://ascopubs.org/doi/10.1200/JCO.2014.60.3787

PRINCE H M , KIM Y H , HORWITZ S M , et al . Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [J ] . Lancet , 2017 , 390 ( 10094 ): 555 - 566 . DOI: 10.1016/S0140-6736(17)31266-7 http://doi.org/10.1016/S0140-6736(17)31266-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673617312667 https://linkinghub.elsevier.com/retrieve/pii/S0140673617312667

HORWITZ S M , ADVANI R H , BARTLETT N L , et al . Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin [J ] . Blood , 2014 , 123 ( 20 ): 3095 - 3100 . DOI: 10.1182/blood-2013-12-542142 http://doi.org/10.1182/blood-2013-12-542142 https://ashpublications.org/blood/article/123/20/3095/32718/Objective-responses-in-relapsed-Tcell-lymphomas https://ashpublications.org/blood/article/123/20/3095/32718/Objective-responses-in-relapsed-Tcell-lymphomas

ZINZANI P L , SANTORO A , GRITTI G , et al . Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase Ⅱ CheckMate 436 study [J ] . J Clin Oncol , 2019 , 37 ( 33 ): 3081 - 3089 . DOI: 10.1200/JCO.19.01492 http://doi.org/10.1200/JCO.19.01492 https://ascopubs.org/doi/10.1200/JCO.19.01492 https://ascopubs.org/doi/10.1200/JCO.19.01492

KIM Y H , TAVALLAEE M , SUNDRAM U , et al . Phase Ⅱ investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project [J ] . J Clin Oncol , 2015 , 33 ( 32 ): 3750 - 3758 . DOI: 10.1200/JCO.2014.60.3969 http://doi.org/10.1200/JCO.2014.60.3969 https://ascopubs.org/doi/10.1200/JCO.2014.60.3969 https://ascopubs.org/doi/10.1200/JCO.2014.60.3969

JACOBSEN E D , SHARMAN J P , OKI Y , et al . Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression [J ] . Blood , 2015 , 125 ( 9 ): 1394 - 1402 . DOI: 10.1182/blood-2014-09-598763 http://doi.org/10.1182/blood-2014-09-598763 https://ashpublications.org/blood/article/125/9/1394/34206/Brentuximab-vedotin-demonstrates-objective https://ashpublications.org/blood/article/125/9/1394/34206/Brentuximab-vedotin-demonstrates-objective

Views

4225

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Research status and progress of third-line treatment for metastatic colorectal cancer

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Related Author

Pathology Expert Group CD30-Positive Lymphoma

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

LIU Miao

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

AI问答

⁰